AlpInvest Partners’s Larimar Therapeutics LRMR Stock Holding History

AlpInvest Partners’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,901	Closed	-$56K	–	24
2019 Q2	$56K	Hold	3,901	–	–	0.05%	29
2019 Q1	$128K	Hold	3,901	–	–	0.17%	26
2018 Q4	$232K	Hold	3,901	–	–	0.67%	19
2018 Q3	$547K	Sell	3,901 -7,800	-67%	-$947K	1.17%	13
2018 Q2	$1.44M	Buy	+11,701	New	+$994K	5.99%	6
2015 Q3	–	Sell	-10,731	Closed	-$4.46M	–	30
2015 Q2	$4.46M	Buy	+10,731	New	+$4.49M	5.64%	9

Other funds holding LRMR

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AlpInvest Partners's LRMR Position: Q3 2019 in Review

AlpInvest Partners sold out of Larimar Therapeutics (LRMR) in Q3 2019, closing a stake of 3,901 shares — an estimated $56K sold.

AlpInvest Partners first reported a position in LRMR in Q2 2015 and held it in 6 quarters. The position peaked at $4.46M in Q2 2015. 51 funds tracked by Wall St. Rank hold LRMR as of Q3 2019.

AlpInvest Partners reported no remaining Larimar Therapeutics position as of Q3 2019 after selling out during the quarter.
AlpInvest Partners sold 3,901 Larimar Therapeutics shares in Q3 2019, an estimated $56K.
AlpInvest Partners first reported a position in Larimar Therapeutics in Q2 2015 and held it in 6 quarters.
AlpInvest Partners's Larimar Therapeutics position peaked at $4.46M in Q2 2015.
51 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2019.

Based on AlpInvest Partners's 13F filing for Q3 2019, filed 13 Nov 2019.